Table 2. Functionally validated miR-29 targets in hematologic neoplasias.
| Target | Neoplasia | miR-29 family member | Reference |
|---|---|---|---|
| MCL-1 | MM, AML | miR-29b | [27] [155] |
| CDK6 | MM, AML, B-cell lymphomas, MCL | miR-29a/b/c | [27] [155] [177] |
| CXXC6 | AML | miR-29b | [42] |
| TCL-1 | CLL | miR-29b | [149] |
| SP1 | AML, MM | miR-29b | [42] [28] |
| DNMT3A/B | AML, MM | miR-29b | [42] [28] |
| AKT2 | AML | miR-29a/b/c | [165] |
| CCND2 | AML | miR-29a/b/c | [165] |
| ABL1 | CML | miR-29b | [173] |
| RNASE-L | CML | miR-29a/b/c | [174] |
| PSME4 | MM | miR-29b | [131] |
| MMP2 | MM-BD | miR-29b | [30] |
| c-FOS | MM-BD | miR-29b | [30] |
| CCNT2 | AML | miR-29a | [161] |
| IGF1R | B-cell lymphomas | miR-29a/c | [178] |
Abbreviations: AML, Acute Myeloid Leukemia; CLL: Chronic Lymphocytic Leukemia; CML, Chronic Myeloid Leukemia; MCL: Mantle Cell Lymphoma; MM, Multiple Myeloma; MM-BD, Multiple Myeloma-related Bone Disease.